Dodge & Cox Sells 135,395 Shares of Elanco Animal Health Incorporated $ELAN

Dodge & Cox lowered its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 0.2% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 82,759,837 shares of the company’s stock after selling 135,395 shares during the period. Dodge & Cox owned about 16.66% of Elanco Animal Health worth $1,666,783,000 as of its most recent SEC filing.

Other hedge funds have also added to or reduced their stakes in the company. AlphaQuest LLC grew its stake in Elanco Animal Health by 13.7% in the third quarter. AlphaQuest LLC now owns 5,953 shares of the company’s stock valued at $120,000 after acquiring an additional 718 shares during the period. Jones Financial Companies Lllp raised its position in shares of Elanco Animal Health by 15.2% during the third quarter. Jones Financial Companies Lllp now owns 6,065 shares of the company’s stock worth $119,000 after purchasing an additional 798 shares during the period. MTM Investment Management LLC raised its position in shares of Elanco Animal Health by 5.5% during the second quarter. MTM Investment Management LLC now owns 15,268 shares of the company’s stock worth $218,000 after purchasing an additional 800 shares during the period. US Bancorp DE lifted its holdings in shares of Elanco Animal Health by 1.9% during the 3rd quarter. US Bancorp DE now owns 43,810 shares of the company’s stock valued at $882,000 after purchasing an additional 824 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. lifted its holdings in shares of Elanco Animal Health by 80.3% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 2,021 shares of the company’s stock valued at $42,000 after purchasing an additional 900 shares in the last quarter. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 1.2%

NYSE:ELAN opened at $22.95 on Friday. The company has a market cap of $11.41 billion, a P/E ratio of -47.80, a price-to-earnings-growth ratio of 2.89 and a beta of 1.83. Elanco Animal Health Incorporated has a twelve month low of $8.02 and a twelve month high of $27.72. The business has a 50 day moving average price of $24.52 and a two-hundred day moving average price of $22.19. The company has a quick ratio of 1.08, a current ratio of 2.17 and a debt-to-equity ratio of 0.60.

Elanco Animal Health (NYSE:ELAN) last posted its quarterly earnings data on Tuesday, February 24th. The company reported $0.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.02. Elanco Animal Health had a negative net margin of 4.92% and a positive return on equity of 7.16%. The company had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same period last year, the company earned $0.14 earnings per share. The firm’s revenue was up 12.2% compared to the same quarter last year. Elanco Animal Health has set its Q1 2026 guidance at 0.330-0.36 EPS and its FY 2026 guidance at 1.000-1.060 EPS. As a group, analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ELAN. UBS Group reissued a “buy” rating on shares of Elanco Animal Health in a research note on Tuesday. JPMorgan Chase & Co. upped their price target on shares of Elanco Animal Health from $24.00 to $28.00 and gave the company an “overweight” rating in a report on Thursday, February 19th. Leerink Partners increased their price objective on shares of Elanco Animal Health from $26.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 24th. KeyCorp raised their price objective on shares of Elanco Animal Health from $27.00 to $29.00 and gave the stock an “overweight” rating in a report on Wednesday, February 25th. Finally, Morgan Stanley boosted their price objective on shares of Elanco Animal Health from $22.00 to $24.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 25th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has a consensus rating of “Moderate Buy” and an average price target of $27.67.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.